nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

11. Probiotics as Edible Vaccines

verfasst von : Anjali Pandya, Sreeranjini Pulakkat, Sarika Jadhav, Vandana Patravale

Erschienen in: Probiotic Research in Therapeutics

Verlag: Springer Singapore

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

The expansion in the knowledge and applications of probiotics is on a constant rise over decades. The history of vaccine development, on the other hand, ranges back to the early nineteenth century and has been advancing ever since. Design of probiotic-based vaccine has been a boon and can be an important contributor in the field of immunization. Building up the human immunological tolerance has been the aim in order to achieve a superior level of human longevity. Orally deliverable vaccines have been preferred over the conventional parenteral formulations owing to their high patient compliance and ease of delivery. Bacteria and yeast are among the most prevalent microbiota utilized as probiotics, and owing to their significant immunomodulatory effects, they have garnered attention as promising candidates for developing edible vaccine. A legion of organisms has been regarded as safe for human consumption, thereby encouraging their adoption into probiotic-based vaccine development. A variety of bacteria- and yeast-based edible probiotic vaccines are highlighted in this chapter catering to a plethora of physiological conditions in humans. The chapter is majorly devoted to representation of the most frequently applied strategies involving bacteria and yeast in the conception of oral probiotic vaccines, both preclinically and clinically. Despite the presence of conglomerate vaccine-based strategies, a quest for newer probiotic oral vaccine platforms still persists.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Safety Concerns, Regulatory Guidelines, Current Market Trends, and Future Directions toward the Use of Probiotics in Gut-Brain-Skin Axis

Acevedo R, Fernández S, Zayas C et al (2014) Bacterial outer membrane vesicles and vaccine applications. Front Immunol 5:121. https://doi.org/10.3389/fimmu.2014.00121CrossRefPubMedPubMedCentral

Ada G (1998) Vaccines. In: Encyclopedia of immunology. Elsevier, Amsterdam, pp 2456–2462CrossRef

Arnold M, Durairaj V, Mundt E et al (2012) Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit. PLoS One 7:e42870. https://doi.org/10.1371/journal.pone.0042870CrossRefPubMedPubMedCentral

Arora U, Tyagi P, Swaminathan S, Khanna N (2013) Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. Vaccine 31:873–878. https://doi.org/10.1016/j.vaccine.2012.12.016CrossRefPubMed

Asensi GF, de Sales NFF, Dutra FF et al (2013) Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model. Microb Cell Factories 12:32. https://doi.org/10.1186/1475-2859-12-32CrossRef

van Baarlen P, Wells JM, Kleerebezem M (2013) Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol 34:208–215. https://doi.org/10.1016/j.it.2013.01.005CrossRefPubMed

Benno Y, Mitsuoka T (1992) Impact of Bifidobacterium longum on human fecal microflora. Microbiol Immunol 36:683–694. https://doi.org/10.1111/j.1348-0421.1992.tb02071.xCrossRefPubMed

Bermúdez-Humarán LG, Aubry C, Motta J-P et al (2013) Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 16:278–283. https://doi.org/10.1016/j.mib.2013.06.002CrossRefPubMed

Blanquet S, Antonelli R, Laforet L et al (2004) Living recombinant Saccharomyces cerevisiae secreting proteins or peptides as a new drug delivery system in the gut. J Biotechnol 110:37–49. https://doi.org/10.1016/j.jbiotec.2004.01.012CrossRefPubMed

Boge T, Rémigy M, Vaudaine S et al (2009) A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 27:5677–5684. https://doi.org/10.1016/j.vaccine.2009.06.094CrossRefPubMed

Bolhassani A, Muller M, Roohvand F et al (2014) Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. Hum Vaccin Immunother 10:3499–3508. https://doi.org/10.4161/21645515.2014.979606CrossRefPubMed

Callaghan AO, Van Sinderen D (2016) Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 7:925. https://doi.org/10.3389/fmicb.2016.00925CrossRef

Chattha KS, Vlasova AN, Kandasamy S et al (2013) Probiotics and colostrum/milk differentially affect neonatal humoral immune responses to oral rotavirus vaccine. Vaccine 31:1916–1923. https://doi.org/10.1016/j.vaccine.2013.02.020CrossRefPubMedPubMedCentral

Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV (2011) Production and evaluation of dry alginate-chitosan microcapsules as an enteric delivery vehicle for probiotic bacteria. Biomacromolecules 12:2834–2840. https://doi.org/10.1021/bm200576hCrossRefPubMed

Criscuolo E, Caputo V, Diotti RA et al (2019) Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines. J Immunol Res 2019:13. https://doi.org/10.1155/2019/8303648CrossRef

Darby RAJ, Cartwright SP, Dilworth MV, Bill RM (2012) Which yeast species shall I choose? Saccharomyces cerevisiae versus Pichia pastoris (review). In: Bill RM (ed) Recombinant protein production in yeast: methods and protocols. Humana Press, Totowa, pp 11–23CrossRef

De Barros JMS, Scherer T, Charalampopoulos D et al (2014) A laminated polymer film formulation for enteric delivery of live vaccine and probiotic bacteria. J Pharm Sci 103:2022–2032. https://doi.org/10.1002/jps.23997CrossRefPubMed

Dieleman LA, Goerres MS, Arends A et al (2003) Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52:370–376. https://doi.org/10.1136/gut.52.3.370CrossRefPubMedPubMedCentral

Earl AM, Losick R, Kolter R (2008) Ecology and genomics of Bacillus subtilis. Trends Microbiol 16:269–275CrossRefPubMedPubMedCentral

Ferreira LCS, Ferreira RCC, Schumann W (2005) Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors. An Acad Bras Cien 77:113–124. https://doi.org/10.1590/S0001-37652005000100009CrossRef

Forsythe P, Bienenstock J (2010) Immunomodulation by commensal and probiotic bacteria. Immunol Investig 39:429–448. https://doi.org/10.3109/08820131003667978CrossRef

Franzusoff A, Duke RC, King TH et al (2005) Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 5:565–575. https://doi.org/10.1517/14712598.5.4.565CrossRefPubMed

Fu LL, Li WF, Du HH et al (2008) Oral vaccination with envelope protein VP28 against white spot syndrome virus in Procambarus clarkii using Bacillus subtilis as delivery vehicles. Lett Appl Microbiol 46:581–586. https://doi.org/10.1111/j.1472-765X.2008.02355.xCrossRefPubMed

Fujisawa Y, Ito Y, Sasada R et al (1983) Direct expression of hepatitis B surface antigen gene in E. coli. Nucleic Acids Res 11:3581–3591. https://doi.org/10.1093/nar/11.11.3581CrossRefPubMedPubMedCentral

Fujiwara D, Inoue S, Wakabayashi H, Fujii T (2004) The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol 135:205–215. https://doi.org/10.1159/000081305CrossRefPubMed

Gaggar A, Coeshott C, Apelian D et al (2014) Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 32:4925–4931. https://doi.org/10.1016/j.vaccine.2014.07.027CrossRefPubMed

Gao S, Li D, Liu Y et al (2015) Oral immunization with recombinant hepatitis E virus antigen displayed on the Lactococcus lactis surface enhances ORF2-specific mucosal and systemic immune responses in mice. Int Immunopharmacol 24:140–145. https://doi.org/10.1016/j.intimp.2014.10.032CrossRefPubMed

Gomes AMP, Malcata FX (1999) Bifidobacterium spp. and Lactobacillus acidophilus: biological, biochemical, technological and therapeutical properties relevant for use as probiotics. Trends Food Sci Technol 10:139–157. https://doi.org/10.1016/S0924-2244(99)00033-3CrossRef

Gurramkonda C, Zahid M, Nemani SK et al (2013) Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties. J Chromatogr B 940:104–111. https://doi.org/10.1016/j.jchromb.2013.09.030CrossRef

Haller AA, Lauer GM, King TH et al (2007) Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 25:1452–1463. https://doi.org/10.1016/j.vaccine.2006.10.035CrossRefPubMed

Hernández-Bernal F, Aguilar-Betancourt A, Aljovin V et al (2011) Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. Hum Vaccin 7:1026–1036. https://doi.org/10.4161/hv.7.10.15989CrossRefPubMed

Hill C, Guarner F, Reid G et al (2014) The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514. https://doi.org/10.1038/nrgastro.2014.66CrossRefPubMed

Hilleman MR (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine, In, pp 1436–1447

Holst J, Oster P, Arnold R et al (2013) Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 9:1241–1253. https://doi.org/10.4161/hv.24129CrossRefPubMedPubMedCentral

Hu B, Li C, Lu H et al (2011) Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit. J Virol Methods 171:272–279. https://doi.org/10.1016/j.jviromet.2010.11.023CrossRefPubMed

Huang H, Ostroff GR, Lee CK et al (2013) Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol 20:1585–1591. https://doi.org/10.1128/CVI.00463-13CrossRefPubMedPubMedCentral

Jacob D, Ruffie C, Dubois M et al (2014) Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. PLoS One 9:e86658–e86658. https://doi.org/10.1371/journal.pone.0086658CrossRefPubMedPubMedCentral

Keating GM, Noble S (2003) Recombinant hepatitis B vaccine (Engerix-B®). Drugs 63:1021–1051. https://doi.org/10.2165/00003495-200363100-00006CrossRefPubMed

Kim HJ, Lee JY, Kang HA et al (2014) Oral immunization with whole yeast producing viral capsid antigen provokes a stronger humoral immune response than purified viral capsid antigen. Lett Appl Microbiol 58:285–291. https://doi.org/10.1111/lam.12188CrossRefPubMed

Kumar R, Kumar P (2019) Yeast-based vaccines: new perspective in vaccine development and application. FEMS Yeast Res 19:foz007. https://doi.org/10.1093/femsyr/foz007CrossRefPubMed

Lee S, Belitsky BR, Brinker JP et al (2010) Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol 17:1647–1655. https://doi.org/10.1128/CVI.00135-10CrossRefPubMedPubMedCentral

Lei H, Xu Y, Chen J et al (2010) Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407:319–324. https://doi.org/10.1016/j.virol.2010.08.007CrossRefPubMed

Lei W-T, Shih P-C, Liu S-J et al (2017) Effect of probiotics and prebiotics on immune response to influenza vaccination in adults: a systematic review and meta-analysis of randomized controlled trials. Nutrients 9:1175. https://doi.org/10.3390/nu9111175CrossRefPubMedCentral

Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol 24:2–6. https://doi.org/10.3109/00365528909091339CrossRef

Levine MM (2006) Enteric infections and the vaccines to counter them: future directions. Vaccine 24:3865–3873. https://doi.org/10.1016/j.vaccine.2006.03.039CrossRefPubMed

Li J, Zhang D, Ma R et al (2013) Preclinical evaluation of a two-dose vaccination schedule of recombinant Hansenula polymorpha hepatitis B vaccine in animals. Hum Vaccin Immunother 9:736–743. https://doi.org/10.4161/hv.23227CrossRefPubMedPubMedCentral

Linares DM, Ross P, Stanton C (2016) Beneficial microbes: the pharmacy in the gut. Bioengineered 7:11–20. https://doi.org/10.1080/21655979.2015.1126015CrossRefPubMed

Link-Amster H, Rochat F, Saudan KY et al (1994) Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 10:55–63. https://doi.org/10.1111/j.1574-695X.1994.tb00011.xCrossRefPubMed

Liu Z, Zhou G, Ren C et al (2016) Oral administration of myostatin-specific recombinant Saccharomyces cerevisiae vaccine in rabbit. Vaccine 34:2378–2382. https://doi.org/10.1016/j.vaccine.2016.03.036CrossRefPubMed

Lok AS, Pan CQ, Han S-HB et al (2016) Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 65:509–516. https://doi.org/10.1016/j.jhep.2016.05.016CrossRefPubMed

Ma Y, Luo Y, Huang X et al (2012) Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli. Microbiology 158:498. https://doi.org/10.1099/mic.0.049932-0CrossRefPubMed

Maclennan CA, Mutreja A (2016) New approaches for needed vaccines. In: Bacteria. Elsevier, Amsterdam, pp 311–329. https://doi.org/10.1016/B978-0-12-802174-3/00016-3CrossRef

Madsen KL, Doyle JS, Jewell LD et al (1999) Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107–1114. https://doi.org/10.1016/s0016-5085(99)70013-2CrossRefPubMed

Maidens C, Childs C, Przemska A et al (2013) Modulation of vaccine response by concomitant probiotic administration. Br J Clin Pharmacol 75:663–670. https://doi.org/10.1111/j.1365-2125.2012.04404.xCrossRefPubMedPubMedCentral

Majamaa H, Isolauri E, Saxelin M, Vesikari T (1995) Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 20:333–383. https://doi.org/10.1097/00005176-199504000-00012CrossRefPubMed

Manfrão-Netto JHC, Gomes AMV, Parachin NS (2019) Advances in using Hansenula polymorpha as chassis for recombinant protein production. Front Bioeng Biotechnol 7:94. https://doi.org/10.3389/fbioe.2019.00094CrossRefPubMedPubMedCentral

Mauras A, Chain F, Faucheux A et al (2018) A new Bifidobacteria Expression SysTem (BEST) to produce and deliver Interleukin-10 in Bifidobacterium bifidum. Front Microbiol 9:1–12. https://doi.org/10.3389/fmicb.2018.03075CrossRef

Miraglia del Giudice M (2014) Probiotics and vaccination in children. J Vaccines Vaccin 5:3. https://doi.org/10.4172/2157-7560.1000226CrossRef

Mishra N, Gupta PN, Khatri K et al (2008) Edible vaccines: a new approach to oral immunization. Indian J Biotechnol 7:283

Mobergslien A, Vasovic V, Mathiesen G et al (2015) Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells. Hum Vaccin Immunother 11:2664–2673. https://doi.org/10.1080/21645515.2015.1056952CrossRefPubMedPubMedCentral

Munson S, Parker J, King TH et al (2007) Coupling innate and adaptive immunity with yeast-based Cancer immunotherapy. In: Cancer vaccines and tumor immunity. Wiley, Chichester, pp 131–149CrossRef

Nielsen J (2013) Production of biopharmaceutical proteins by yeast: advances through metabolic engineering. Bioengineered 4:207–211. https://doi.org/10.4161/bioe.22856CrossRefPubMed

Norheim G, Tunheim G, Næss LM et al (2012) An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scand J Immunol 76:99–107. https://doi.org/10.1111/j.1365-3083.2012.02709.xCrossRefPubMed

Novik G, Savich V (2020) Beneficial microbiota. Probiotics and pharmaceutical products in functional nutrition and medicine. Microbes Infect 22:8. https://doi.org/10.1016/j.micinf.2019.06.004CrossRefPubMed

O’Callaghan D, Maskell D, Liew FY et al (1988) Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun 56:419–423CrossRefPubMedPubMedCentral

Park S-M, Mo A-Y, Lim J-G et al (2007) Surface displayed expression of a neutralizing epitope of spike protein from a Korean strain of porcine epidemic diarrhea virus. Biotechnol Bioprocess Eng 12:690–695. https://doi.org/10.1007/BF02931087CrossRefPubMedPubMedCentral

Perdigón G, Maldonado Galdeano C, Valdez JC, Medici M (2002) Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 56(suppl 4):S21–S26. https://doi.org/10.1038/sj.ejcn.1601658CrossRefPubMed

Permpoonpattana P, Hong HA, Phetcharaburanin J et al (2011) Immunization with Bacillus spores expressing toxin a peptide repeats protects against infection withClostridium difficile strains producing toxins A and B. Infect Immun 79:2295. https://doi.org/10.1128/IAI.00130-11CrossRefPubMedPubMedCentral

Pouwels PH, Leer RJ, Shaw M et al (1998) Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol 41:155–167. https://doi.org/10.1016/S0168-1605(98)00048-8CrossRefPubMed

Preising J, Philippe D, Gleinser M et al (2010) Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. Appl Environ Microbiol 76:3048–3051. https://doi.org/10.1128/AEM.03127-09CrossRefPubMedPubMedCentral

Probiotics Market Size, Growth | Industry Report by 2025. (n.d.). https://www.fortunebusinessinsights.com/industry-reports/probiotics-market-100083. Accessed 31 Oct 2019

Ren C, Zhang Q, Wang G et al (2014) Modulation of peanut-induced allergic immune responses by oral lactic acid bacteria-based vaccines in mice. Appl Microbiol Biotechnol 98:6353–6364. https://doi.org/10.1007/s00253-014-5678-7CrossRefPubMed

Riedel CU, Foata F, Philippe D et al (2006) Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation. World J Gastroenterol 12:3729–3735. https://doi.org/10.3748/wjg.v12.i23.3729CrossRefPubMedPubMedCentral

Rosales-Mendoza S, Angulo C, Meza B (2016) Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends Biotechnol 34:124–136. https://doi.org/10.1016/j.tibtech.2015.11.007CrossRefPubMed

Saegusa S, Totsuka M, Kaminogawa S, Hosoi T (2009) Saccharomyces cerevisiae and Candida albicans stimulate cytokine secretion from human neutrophil-like HL-60 cells differentiated with retinoic acid or dimethylsulfoxide. Biosci Biotechnol Biochem 73:2600–2608. https://doi.org/10.1271/bbb.90410CrossRefPubMed

Schreuder MP, Deen C, Boersma WJA et al (1996) Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine 14:383–388. https://doi.org/10.1016/0264-410X(95)00206-GCrossRefPubMed

Schultz M, Veltkamp C, Dieleman LA et al (2002) Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8:71–80. https://doi.org/10.1097/00054725-200203000-00001CrossRefPubMed

Setoyama H, Imaoka A, Ishikawa H, Umesaki Y (2003) Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect 5:115–122. https://doi.org/10.1016/S1286-4579(02)00080-1CrossRefPubMed

Shiba T, Aiba Y, Ishikawa H et al (2003) The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol 47:371–378. https://doi.org/10.1111/j.1348-0421.2003.tb03368.xCrossRefPubMed

Shin SJ, Bae JL, Cho Y-W et al (2005) Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Med Microbiol 43:155–164. https://doi.org/10.1016/j.femsim.2004.07.004CrossRefPubMed

Shin SJ, Shin SW, Kang ML et al (2007) Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. J Vet Sci 8:383–392. https://doi.org/10.4142/jvs.2007.8.4.383CrossRefPubMedPubMedCentral

Shin M-K, Lee W-J, Jung MH et al (2013) Oral immunization of mice with Saccharomyces cerevisiae expressing a neutralizing epitope of ApxIIA exotoxin from Actinobacillus pleuropneumoniae induces systemic and mucosal immune responses. Microbiol Immunol 57:417–425. https://doi.org/10.1111/1348-0421.12053CrossRefPubMed

Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084–1089. https://doi.org/10.1126/science.aac4255CrossRefPubMedPubMedCentral

Stearns T, Ma H, Botstein D (1990) Manipulating yeast genome using plasmid vectors. In: Methods in enzymology. Academic, Boston, pp 280–297

Strukelj B, Berlec A, Ravnikar M (2012) Lactic acid bacteria as oral delivery systems for biomolecules. Pharmazie 67:891–898. https://doi.org/10.1691/ph.2012.1705CrossRefPubMed

Stubbs AC, Martin KS, Coeshott C et al (2001) Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7:625CrossRefPubMed

Tunheim G, Arnemo M, Næss LM et al (2013) Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines. Vaccine 31:6097–6106. https://doi.org/10.1016/j.vaccine.2013.09.044CrossRefPubMed

Tursi A, Brandimarte G, Giorgetti GM, Elisei W (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 40:312–316. https://doi.org/10.1097/01.mcg.0000210092.77296.6dCrossRefPubMed

Tursi A, Brandimarte G, Giorgetti GM, Elisei W (2008) Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepato-Gastroenterology 55:916–920PubMed

Tursi A, Brandimarte G, Elisei W et al (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38:741–751. https://doi.org/10.1111/apt.12463CrossRefPubMed

Ursell LK, Metcalf JL, Parfrey LW, Knight R (2012) Defining the human microbiome. Nutr Rev 70(suppl 1):S38–S44. https://doi.org/10.1111/j.1753-4887.2012.00493.xCrossRefPubMed

Vetter V, Denizer G, Friedland LR et al (2018) Understanding modern-day vaccines: what you need to know. Ann Med 50:110–120. https://doi.org/10.1080/07853890.2017.1407035CrossRefPubMed

Vitetta L, Saltzman ET, Thomsen M et al (2017) Adjuvant probiotics and the intestinal microbiome: enhancing vaccines and immunotherapy outcomes. Vaccine 5:1–17. https://doi.org/10.3390/vaccines5040050CrossRef

Wang M, Jiang S, Wang Y (2016) Recent advances in the production of recombinant subunit vaccines in Pichia pastoris. Bioengineered 7:155–165. https://doi.org/10.1080/21655979.2016.1191707CrossRefPubMedPubMedCentral

Wi GR, Hwang JY, Kwon M-G et al (2015) Protective immunity against nervous necrosis virus in convict grouper Epinephelus septemfasciatus following vaccination with virus-like particles produced in yeast Saccharomyces cerevisiae. Vet Microbiol 177:214–218. https://doi.org/10.1016/j.vetmic.2015.02.021CrossRefPubMed

Yasui H, Shida K, Matsuzaki T, Yokokura T (1999) Immunomodulatory function of lactic acid bacteria. Antonie van Leeuwenhoek Int J Gen Mol Microbiol 76:383–389CrossRef

Yi E-J, Shin Y-J, Kim J-H et al (2017) Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res 6:4–14. https://doi.org/10.7774/cevr.2017.6.1.4CrossRefPubMedPubMedCentral

Yousefi B, Eslami M, Ghasemian A et al (2019) Probiotics importance and their immunomodulatory properties. J Cell Physiol 234:8008–8018. https://doi.org/10.1002/jcp.27559CrossRefPubMed

Yu Z, Huang Z, Sao C et al (2013) Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. Arch Virol 158:1071–1077. https://doi.org/10.1007/s00705-012-1589-zCrossRefPubMed

Zhang T, Yang H, Wang R et al (2011) Oral administration of myostatin-specific whole recombinant yeast Saccharomyces cerevisiae vaccine increases body weight and muscle composition in mice. Vaccine 29:8412–8416. https://doi.org/10.1016/j.vaccine.2011.08.007CrossRefPubMed

Zhang T, Sun L, Xin Y et al (2012) A vaccine grade of yeast Saccharomyces cerevisiae expressing mammalian myostatin. BMC Biotechnol 12:97–97. https://doi.org/10.1186/1472-6750-12-97CrossRefPubMedPubMedCentral

Zhou Z, Xia H, Hu X et al (2008) Oral administration of a Bacillus subtilis spore-based vaccine expressing Clonorchis sinensis tegumental protein 22.3 kDa confers protection against Clonorchis sinensis. Vaccine 26:1817–1825. https://doi.org/10.1016/j.vaccine.2008.02.015CrossRefPubMed

Zhou Z, Gong S, Li X-M et al (2015) Expression of Helicobacter pylori urease B on the surface of Bacillus subtilis spores. J Med Microbiol 64:104–110. https://doi.org/10.1099/jmm.0.076430-0CrossRefPubMed

Zimmermann P, Curtis N (2018) The influence of probiotics on vaccine responses – a systematic review. Vaccine 36:207–213. https://doi.org/10.1016/j.vaccine.2017.08.069CrossRefPubMed

Zocco MA, Dal Verme LZ, Cremonini F et al (2006) Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23:1567–1574. https://doi.org/10.1111/j.1365-2036.2006.02927.xCrossRefPubMed

Titel: Probiotics as Edible Vaccines
verfasst von: Anjali Pandya
Sreeranjini Pulakkat
Sarika Jadhav
Vandana Patravale
Verlag: Springer Singapore
Buch: Probiotic Research in Therapeutics
Print ISBN: 978-981-16-5627-9

Electronic ISBN: 978-981-16-5628-6

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-981-16-5628-6_11

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Springer Professional "Wirtschaft"